Open access peer-reviewed chapter

Immunotherapy for Fungal Infections

Written By

Érico S. Loreto, Juliana S. M. Tondolo, Sydney H. Alves and Janio M. Santurio

Submitted: June 1st, 2016 Reviewed: October 5th, 2016 Published: April 26th, 2017

DOI: 10.5772/66164

Chapter metrics overview

1,686 Chapter Downloads

View Full Metrics

Abstract

Opportunistic fungal infections are a major health problem being appointed by some studies as the fourth main cause of hospital-acquired infection in susceptible populations. The constantly growing incidences of these diseases are associated with the growing number of susceptible individuals, such as immunocompromised individuals (leukemia, AIDS, etc) and treatment-induced immunodeficiency (hematopoietic stem cell, solid organ transplant, anticancer therapy). Furthermore, other advances in medical care, patient’s long-term hospitalization and antimicrobial therapies have created several vulnerable populations to fungal infections. Currently, antifungal drug therapies are several times inefficient, and the poor outcomes are linked to difficulties in the early diagnosis of fungal infections and drug resistance among fungal pathogens. In this context, novel therapeutic approaches are welcome to stimulate efficiently the host immune response to eliminate the fungal pathogen. This chapter is intended to review advances in immunotherapy strategies for fungal infections.

Keywords

  • immunotherapy
  • vaccination
  • immune enhancement
  • fungal infections
  • antifungal

1. Introduction

Fungi are eukaryotic organisms ubiquitous in the environment, are considered the major decomposers in certain ecosystems, are essential to the survival of many organisms which they can be associated and are sources of food, several enzymes and drugs. There is an estimate of the existence of more than 5 million of fungal species, of that around 70,000 were described [1]. However, only a few hundred of them can also cause disease in healthy and immunocompromised humans [2, 3]. It was accepted that fungi and other pathogenic microorganisms can cause disease all by themselves through four basic conditions, also known as “virulence factors”: (i) tolerance to the host body temperature; (ii) ability to colonize and/or invade the host; (iii) production of secreted components such as toxin and proteolytic enzymes associated with the processes of lysis and absorption of host tissue and (iv) evasion and/or resistance to the host immune system [2, 4].

Based on this germ theory, antimicrobial therapies options targeted these virulence factors and have focused on the development of pharmacological products designed to kill the pathogenic microorganisms and immunological interventions that overcame the deleterious effects of their virulence factors [5]. Interestingly, the Damage-Response Framework theory, which was first proposed in 1999, emphasizes that disease state is not unidirectional and that both the pathogenic microorganism and the host contribute to pathogenicity and virulence [6]. Additionally, recent studies on the human mycobiome, that is, the collection of fungi distributed across and within the body, show that despite being as low as ≤0.1% of the total microbiota, these microorganisms can participate and modify several physiological functions of the host, including the maintenance of microbiota community structure, metabolic functions and in the development and function of the immune system [7].

Fungal infections contribute substantially to human morbidity and mortality, and despite the availability of several antifungal drugs, high rates of mortality associated with invasive fungal infections often exceed 50% [8]. In this context, in order to achieve a reduction in the global burden of fungal infections, is urgent the development of new safer and more effective antifungal drugs [9], as well as novel immunotherapeutic strategies that allow the restoration of the host immune system [10] and maintain or improve the favorable interactions between microbiota and host [11]. In this context, immunotherapy represents a therapeutic modality that attempts to augment host immune response and to control the established infection. In this chapter, we review the principles of antifungal immunotherapy.

Advertisement

2. Immunological aspects of fungal infections

The host defense mechanisms against fungi range from the protective mechanisms provided by skin, mucosa and innate immunity to sophisticated adaptive mechanisms (adaptive immunity), which are specifically induced during the fungal infection/disease. The activation of the innate immunity is the first line of host antifungal defenses and is mediated by phagocytic cells (polymorphonuclear and mononuclear leukocytes and dendritic cells (DCs)), cellular receptors and several humoral factors that act by (i) direct destruction of the fungi through phagocytic process or secretion of microbicide compounds and/or (ii) initiation and subsequent direction of adaptive immune responses through the production of pro-inflammatory mediators (chemokines and cytokines), induction of co-stimulatory activity by phagocytic cells and uptake, processing and presentation of antigens [12, 13].

The components of the fungal cell wall are the first structures that interact with the host innate immune system, and the response to a fungal invasion is initiated through recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) present during infection by pattern recognition receptors (PRRs). The PRRs are present in the immune cells of the myeloid lineage (dendritic cells, macrophages, monocytes and neutrophils) and nonmyeloid (epithelial and endothelial cells) [12]. The binding of PRR with fungal PAMPs, such as polysaccharides (chitin, α and β-glucans, mannans) and fungal DNA, results in the activation of intracellular signaling pathways promoting phagocytosis, cytokine production, respiratory burst and cell maturation [14].

Several families of PRRs are related to the recognition of cell wall components of fungi through the use of distinct ligand recognition domains, including Toll-like receptors (TLR), C-type lectin receptors (CLR) and proteins of galectins family [12, 15]. The PRRs present in different phagocytic cells initiate intracellular events that promote the activation of the immune system and clearance of fungi, with the specific immune response generated depending on the cell type involved (monocytes, macrophages and neutrophils) [16]. Induction of innate immunity by means of PRR activation provides the basis for developing a subsequent adaptive immune response, and dendritic cells form the interface between the innate and adaptive immune system, since these cell lineages are able to acquire antigens in peripheral tissues, mature and migrate to lymphoid organs, where they provide appropriate signals to T lymphocytes [17].

The adaptive immunity is generated by clonal selection of lymphocytes in response to specific microbial antigens, which can result in the development of immunological memory. The production of cytokines that occurs after the interaction of PRRs with fungal PAMPs drives in the differentiation of naïve T lymphocyte in different subtypes, such as T helper (Th) 1, Th2, Th17 and T regulatory (Treg). During the response process and after the immune activation, T cell subtypes express different pro- and anti-inflammatory chemokines and cytokines, which mediate different effector functions [18].

It is important to emphasize that a fine balance between pro- and anti-inflammatory signals is a prerequisite for successful control of infection. If on one hand, the early inflammation prevents or limits the fungal infection, on the other hand, the uncontrolled inflammatory response may eventually act in opposition to eradicate the disease [19]. Thus, a successful immune response against a fungal infection requires (i) resistance mechanisms, that is, ability to reduce pathogen burden through innate (e.g., dendritic cells) and adaptive (e.g., Th1, Th2, Th9, Th17 and Th22 cells) immunity and (ii) tolerance mechanisms, that is, ability to protect and/or limit the host from immune- or pathogen-induced damage (e.g., Treg cells and enzymes involved in tryptophan metabolism) [18, 20].

The consensus is that Th1 cellular responses are the main defense mechanism of the host against pathogenic fungi, whereas Th2 responses are associated with susceptibility to infections or allergic responses [21]. Th1 cells are predominantly related to protective immunity against fungi and effective antifungal vaccines [12]. Interferon-γ (IFN-γ) is the main cytokine produced by Th1 cells and is important for the stimulation of the antifungal activity of neutrophils [21]. Interleukin (IL)-4, IL-5 and IL-13 are cytokines produced during Th2 immune responses, promote an alternative route of macrophage activation, favor fungal infections and allergic responses associated with the fungus and may be related to disease recurrence [12].

Th17 responses are characterized by the production of IL-17, working in the host defense against certain extracellular bacteria and fungi [22], and are related to protective vaccine responses against experimental fungal infections [23]. However, Zelante et al. [24] described that IL-23 and the Th17 pathway can also promote inflammation and impair antifungal resistance. Treg cells by IL-10 production have the function of moderating the inflammatory r4"esponse during infection to limit damage to the host cells and restore homeostasis [25]. However, this response may limit the effectiveness of the protective immune response as a result of the reduction of pro-inflammatory activity generating persistence of the fungus in the tissue and can lead to immunosuppression [21].

Advertisement

3. Cell-based therapies

3.1. Granulocyte transfusion

Polymorphonuclear leukocytes are specialized cells found in the bloodstream that can directly attack microorganisms through phagocytosis, release of soluble antimicrobials and generation of neutrophil extracellular traps, playing an essential role in host defense against pathogenic bacteria and opportunistic fungal pathogens [26, 27]. Granulocyte transfusion is reserved for patients with prolonged neutropenia and life-threatening infections that are resistant to conventional treatment and is intended to improve the side effects of neutropenia and enhance repopulation of granulocytes [2831].

Early studies of Strumia [32], Brecher et al. [33] and Freireich et al. [34] are among the pioneering research work to propose the infusion of neutrophilic granulocytes from donors as an option to enhance host defenses in patients with neutropenia. Pedersen et al. [35] reported that the combination of granulocyte transfusion with trimethoprim-sulfamethoxazole resulted in the successful treatment of a refractory Pneumocystis carinii pneumonia in an 11-year-old girl with chronic granulomatous disease. In a retrospective study, Bhatia et al. [36] evaluated the efficacy of granulocyte transfusion in 87 bone marrow transplant recipients during the first 100 days following the transplantation. No clinical benefit of granulocyte transfusion among 50 of these patients could be shown in the resolution of candidiasis or noncandidal infections. In a meta-analysis of 32 studies, Strauss [37] described that from 63 patients with invasive fungal infections and receiving granulocyte transfusion, only 18 (29%) had successful outcomes.

Based on these and other contradictory results, for a period of time, it has been suggested that there is no strong evidence that granulocyte transfusion consistently brings benefits for the treatment of invasive fungal infections. However, the advances in the cytapheresis technology in the last decades optimize the allogeneic or autologous collection of several types of blood leucocytes to be used in transfusion therapies, which renewed the interest in granulocyte infusions [3840].

Price et al. [41], in a phase I/II trial of neutrophil transfusions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexamethasone, demonstrated that four of the seven patients with candidemia cleared the infection and, in contrast, none of the patients with aspergillosis (n = 5) or fusariosis (n = 3) were able to clear the infection. Mousset et al. [42] in a prospective, nonrandomized study demonstrated a good clinical efficacy of granulocyte transfusions to prevent recurrence of severe fungal infections during hematopoietic stem cell transplantation or intensive chemotherapy (23 episodes). However, in a randomized phase III study with 74 neutropenic patients, Seidel et al. [29] concluded that there was no effect on survival of 55 patients with invasive fungal infection up to day 100.

Several case series and case reports [31, 4346] provide evidence for the safety and feasibility of granulocyte transfusions in patients with severe neutropenia and uncontrolled fungal infections. Thus, although the role of therapeutic granulocyte transfusions remains controversial, future randomized controlled studies will clarify the use of the granulocyte transfusion as a life-saving treatment option [47].

3.2. Dendritic cell therapy

Dendritic cells (DCs) are the bridge between the innate and adaptive immune system by sensing the fungal pathogen via their PRRs, phagocytizing fungal particles, processing and secreting cytokines and chemokines into the environment and presenting antigens to Th cells to induce an adaptive immune response [48]. This remarkable functional plasticity of DCs has been explored for the development of fungal vaccines [49], whereas DCs transfected with yeast cells, yeast RNA or conidia (but not hyphae or hyphal RNA) induce a protective Th1 response [50].

Induction of an adoptive immunity to Aspergillus using DCs pulsed with live conidia or transfected with conidial RNA [51] or primed with CpG oligodeoxynucleotides and pulsed with Aspf16 antigens [52] triggers specific and protective Th1 response in murine models of hematopoietic stem cell transplantation (HSCT). DCs transduced with an adenovirus vector encoding the cDNA of IL-12 and pulsed with heat-inactivated Aspergillus fumigatus induce a protective response (lower fungal burdens and higher survival rate) against a model of invasive pulmonary aspergillosis [53]. Stimulation of Asp f16-specific T cell responses are more effective by using a protocol of antigen presented on DC followed by Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (BLCL) as antigen-presenting cells [54].

Protection against disseminated candidiasis in mice was observed with DCs pulsed with cell wall proteins expressed during infection, particularly those derived from fructose-bisphosphate aldolase, which induced a robust antibody-dependent protective responses against Candida albicans [55]. Bone marrow-derived dendritic cells pulsed with an acapsular Cryptococcus gattii strongly induced cytokine-producing CD4 T cells and multinucleated giant cells, and these were associated with a protection against a Cryptococcus gattii model of pulmonary cryptococcosis [56].

3.3. Adoptive T-cell transfer

Adoptive T cell transfer is an immunotherapy strategy used to treat cancer and chronic infections by intravenous injection of autologous T cells, which was, after isolated from the donor, stimulated in vitro with antigens or modified with a gene encoding a specific antigen receptor and expanded to a large quantity before infusion back into the patient [57]. Th1 lymphocyte responses confer significant protection against fungal infections [18], and the pivotal role of CD4+ T cell has led to increasing interest and investigation of the use of adoptive transfer of CD4+ cells in the prophylaxis and treatment of invasive fungal infections [58].

Perruccio et al. [59] used heat-inactivated conidia of A. fumigatus to generate specific T-cell clones in vitro, which was infused soon after hematopoietic transplantation in 35 patients. High-frequency T-cell responses to pathogen within three weeks infusion were associated with control of Aspergillus antigenemia and infectious mortality. In contrast, spontaneous pathogen-specific T cells in 46 transplant recipient patients who did not receive adoptive therapy occurred in low frequency as late as 9–12 months after transplantation and displayed a nonprotective, type-2 cytokine profile. However, commonly used immunosuppressants such as cyclosporine A, mycophenolic acid and methylprednisolone decreased the number of anti-Aspergillus Th1 cells and the expression of CD154 by anti-Aspergillus Th1 cells, which may limit using this type of immunotherapy for organ transplant recipients [60].

Prolonged survival rates were observed in a model of mice invasive pulmonary aspergillosis after the adoptive transfer of splenic CD4+ T cells from mice previously sensitized with a crude culture filtrate antigens of A. fumigatus [61]. In BALB/c mice, the cell glucanase Crf1 from A. fumigatus induces memory CD4+ Th1 and cross-protection against lethal infection with C. albicans [62]. In addition to Crf1, A. fumigatus proteins Gel1 and Pmp20 are described as strong inducers of Th1 responses in healthy individuals [63]. Tramsen et al. [64] reported a clinical scale generation of multi-specific antifungal T cells protocol based on the use of cellular fungal extracts of A. fumigatus, C. albicans and Rhizopus oryzae that allow the generation of numerous activated memory Th1 cells that respond to a broad spectrum of fungal pathogens. The data from these and similar studies [65, 66] support the development of adoptive T-cell transfer protocols for the therapy of multiple microbial pathogens as well as in prophylaxis/vaccination protocols [67].

Despite the main role of CD4+ Th1 cells for host defense against pathogenic fungi, current findings highlight the effector functions of CD8+ T cells against these pathogens [10, 68]. Adoptive transfer of Aspergillus f16 peptide-specific CD8+ T cells extended the overall survival time of A. fumigatus-infected immunocompromised mice [69], supporting alternative adoptive T-cell treatments for hosts with progressive depletion of CD4+ T lymphocytes and at high risk of invasive fungal infections.

3.4. B cell and natural killer cell treatment

B cells and natural killer (NK) cells are other cell lineages that have been evaluated for its antimicrobial activity through adoptive transfer procedures. Hoyt et al. [70] demonstrated that adoptive transfer of B cells into mice lacking both lymphocytes and type I IFN receptor and with Pneumocystis murina lung infection maintained early hematopoietic progenitor activity during immune responses against the infection, thus promoting replenishment of depleted bone marrow cells in an IL-10- and IL-27-dependent manner mechanisms possibly by stimulation of dendritic cells/macrophages.

NK cells are innate lymphocytes that exhibit both adaptive and innate features and that can be activated in the presence of infected cells, allogeneic cells or transformed cells, for acting on antigen-specific recognition and mounting rapid effector responses such as rapid cytolytic and cytokine activity and antibody secretion [71] as well as in the immunological memory process [72]. Park et al. [73] described that the NK cells mediate their protective effect in the lungs of neutropenic mice with invasive aspergillosis by acting as the most important source of IFN-γ during the early stages of infection. Additionally, the transfer of activated NK cells from a wild-type host to both IFN-γ-deficient and wild-type recipients resulted in a more rapid clearance of A. fumigatus from the lungs. Bouzani et al. [74], similarly, concluded that NK cells mediate anti-Aspergillus activity through an alternative mechanism involving IFN-γ and tumor necrosis factor (TNF)-α secretion and not through degranulation of their cytotoxic proteins.

NK cells, directly and indirectly (through IFN-γ), showed killing activity against A. fumigatus hyphae, but lack activity against infecting conidia [75]. Based on these observations, adoptive immunotherapy with NK cells represents a potential alternative to be used alone or in combination with other antifungal therapies, but should have limited role in prophylactic strategies against aspergillosis.

Advertisement

4. Cytokine therapy

Cytokines are intercellular regulatory polypeptides or glycoproteins that promote growth, differentiation and activation of normal cells and play an essential role on immunomodulation and inflammatory processes. If on one hand, the determination of a patient cytokine profile may indicate the status of the disease, on the other hand, the therapeutic administration of cytokines can result in a favorable immunomodulation for the treatment of autoimmune, neoplastic and infectious diseases [76].

4.1. Colony-stimulating factors (CSFs)

Granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF) and GM-CSF are used to accelerate myelopoiesis in neutropenic patients and as immune enhancing agents. G-CSF is widely used during chemotherapy neutropenia in clinical practice to prevent immune dysregulation and accelerated functional immune recovery [77]. G-CSF not only increases neutrophil production but also significantly enhanced polymorphonuclear-mediated killing of A. fumigatus and Rhizopus arrhizus but not against C. albicans [78]. In a mice model of experimental disseminated candidiasis, the treatment with recombinant G-CSF (rG-CSF) leads to significantly reduced mortality. However, it is less effective in subacute or chronic disseminated candidiasis. Additionally, combination of rG-CSF and fluconazole results in an additive effect on the reduction of fungal load in the organs [79]. Combination of G-CSF and caspofungin or caspofungin plus amphotericin B-intralipid reduced the fungal burden in organs, decreased the detection of serum galactomannan and increased survival rate up to 78.9% of infected mice with A. fumigatus [80]. Favorable clinical response was also observed in 15 of 18 patients with mucormycosis [81]. While G-CSF clearly reduces the neutropenic period of patients, more data about clinical outcomes in fungal infections are needed [82, 83].

Human macrophage colony-stimulating factor (hM-CSF) slightly prolonged survival of lethal C. albicans infection in mice and enhanced the efficacy of amphotericin B by enhancing the growth-inhibitory activities of both macrophages and neutrophils against Candida [84]. In a neutropenic rabbit model of pulmonary aspergillosis, M-CSF administered prophylactically significantly increased survival and decreased pulmonary injury, probably through increased phagocytosis of A. fumigatus conidia by alveolar macrophages [85]. Recombinant human macrophage colony-stimulating factor (rhM-CSF) associated with standard antifungal therapy, into a phase I/II trial, was administrated to 46 bone marrow transplant patients from day 0 to 28 after determination of progressive fungal disease. Survival of these patients was higher (27% v 5%) when compared with 58 similar historical controls [86].

GM-CSF significantly enhanced both the killing by neutrophils and monocytes and the collaboration of these cells with voriconazole for killing C. albicans [87]. GM-CSF blocks the in vivo immunosuppressive effects of dexamethasone on bronchoalveolar macrophages, killing of A. fumigatus conidia and suggests its use in patients at risk of pulmonary aspergillosis in the course of dexamethasone treatment [88]. Similarly, Quezada et al. [89] demonstrated that GM-CSF administered intranasally to immunosuppressed mice infected with pulmonary aspergillosis reduced the lung fungal burden compared to the control.

Wildbaum et al. [90] related a patient with chronic mucocutaneous candidiasis that quickly went to a complete clinical remission with improvement in his/her monocyte and neutrophil functions after intravenous GM-CSF treatment (leucomax, 800 mg twice a week). Safdar et al. [91] retrospectively assessed 66 patients in whom GM-CSF was given during antifungal therapy, for which more than half of partial or complete response was observed. Wan et al. [92], in a prospective multicenter randomized phase IV trial with 206 patients, showed that GM-CSG for prophylaxis of infection after allogeneic transplantation was more effective than G-CSF alone in decreasing 100-day cumulative-, transplantation- and infection-related mortalities. Further studies to assess the use and efficacy of CSFs in the treatment of invasive fungal infections are needed.

4.2. Pro-inflammatory cytokines

Several studies demonstrate that immunomodulation with a variety of cytokines can enhance the antifungal activity of neutrophils and monocytes/macrophages as well as upregulation of protective Th1 immune response [93, 94]. Of these, interferon-γ (IFN-γ) produced by T and NK cells is a key cytokine in both the innate and adaptive immune response against invasive fungal infections, for which there are randomized controlled clinical trials [95, 96].

IFN-γ, in vitro, effectively primed neutrophils and mononuclear cells for enhanced fungal damage against A. fumigatus, Fusarium solani and C. albicans, as well as the stimulation of other cytokines [97]. In experimental animal models of fungal infections, IFN-γ had efficacy in a systemic cryptococcosis infection in mice, especially in combination with amphotericin B [98], and enhances host resistance against acute disseminated C. albicans in mice [99] and in murine invasive models of aspergillosis [100, 101]. However, inconsistent results were observed in a murine model of candidiasis when different strains of mice were used [102].

In a phase II, double-blind, placebo-controlled study, Pappas et al. [96] evaluated the safety and antifungal activity of adjuvant therapy with recombinant IFN-γ in patients with AIDS and acute cryptococcal meningitis. The results suggested that recombinant IFN-γ induces a more rapid sterilization of the cerebrospinal fluid and better clinical outcome. Similar results were observed in a randomized controlled trial conducted by Jarvis et al. [95]. The addition of short course IFN-γ (100 or 200 µg) to conventional antifungal therapy significantly increased the rate of negative cerebrospinal fluid culture. Guidelines for management of cryptococcal disease suggest that the adjunctive immunological therapy with recombinant IFN-γ can be considered for refractory cases [103].

The adjunctive immunotherapy with recombinant IFN-γ partially restored cell-mediated immunity and enhanced antifungal immunity in a prospective case series describing eight patients with invasive Candida or Aspergillus infections [104]. Other case reports have described the successful treatment of invasive aspergillosis with the combination of IFN-γ and antifungal therapy [105108]. Adjunctive therapy with interferon-γ, GM-CSF or G-CSF showed good functional outcome in a case of Scedosporium apiospermum otomastoiditis and in a case of Mucor sinusitis and orbital cellulitis refractories to treatment with conventional antifungals [109]. However, for invasive mold infections, more data and randomized controlled clinical trials are needed.

IFN-γ, in combination with antimicrobials drugs, is currently recommended in prophylaxis of patients with chronic granulomatous disease (CGD), a population for which invasive filamentous fungal infections are a persistent problem [108, 110].

IL-12, IL-15 and TNF-α are other pro-inflammatory cytokines that have been assessed in preclinical trials as candidate adjuvant since they also upregulate the antifungal Th1 response [94]. IL-12 plays an obligatory role for the development of a Th1 response to Candida [111] and Cryptococcus neoformans [112], enhances the antifungal capacity of monocytes against A. fumigatus in vitro and has also been explored in immunotherapeutic proposals for various animal models of cryptococcal infections [113]. IL-12 gene therapy enhanced the host response against experimental coccidioidomycosis [114] and accelerated the clearance of infection in a murine Pneumocystis pneumonia model [115]. However, the use of IL-12 as immune enhancer remains controversial because this cytokine may paradoxically increase the susceptibility of the host to fungal pathogens [116, 117].

IL-15 is involved in the innate immunity against fungal infections and, similarly like IL-12, enhances the antifungal activity of granulocyte or monocyte cells against C. albicans, A. fumigatus, Fusarium spp. and Scedosporium spp. [118121]. Although IL-15 has been potential as a new therapeutic option against invasive fungal infections, more information from future preclinical and clinical trials is needed.

TNF-α is necessary for the development of effective immunity to fungal infections [94], enhancing the activity of granulocyte cells against A. fumigatus, C. albicans and Cryptococcus neoformans [93, 122124]. In a murine invasive pulmonary aspergillosis model, antibody-mediated neutralization of TNF-α increases mortality, whereas the intratracheal administration of a TNF-α agonist peptide improved survival [100]. Additionally, stimulatory/protective effect of TNF-α is also described against cryptococcal infections [113].

4.3. Other cytokines

Several other cytokines have been shown to be involved in the immune process during fungal infections and may be targets for future immunotherapy proposals. Gresnigt et al. [125] described the biological relevance of IL-36 in a pathway involved in the induction of Th responses by A. fumigatus. Nlrp3, Asc and caspase-1 mediated Paracoccidioides brasiliensis-induced IL-18, and the activation of the inflammasome is associated with a strong Th1-mediated immune response and, consequently, host antifungal defense against Paracoccidioides brasiliensis [126]. IL-7 is potent immunotherapeutic that acts at multiple levels to improve host immunity. In mice infected intravenously with C. albicans, the treatment with IL-7 weakened the infection and improved the host survival rates [127]. IL-18 contributes to host defense against Cryptococcus neoformans and Paracoccidioides brasiliensis [126, 128].

Advertisement

5. Antibody-based therapy

Antibodies or immunoglobulins are heterodimeric proteins composed of two heavy and two light chains, which are associated with the specific humoral immunity and primary defense against several infectious diseases [129132]. The protective potential of antibodies produced during fungal infections can be accomplished by indirect and direct mechanisms and can vary depending on certain factors, such as the isotype, subisotype and title of antibodies and major histocompatibility complex background of the host [132, 133].

The interest in the potential benefit of antibody-based therapy for invasive fungal infections starts with Dromer et al. [134] describing that the intraperitoneal administration of a monoclonal IgG1 anti-Cryptococcus neoformans antibody could be used as a passive serotherapy, participating in the prevention or treatment of experimental cryptococcosis and with Gigliotti and Hughes [135] describing that the use of the monoclonal antibody (mAb) M5E312 was capable of hindering the development of an experimental murine Pneumocystis carinii infection.

Efungumab (Mycograb®) and the 18B7 (mAb) are two examples of antifungal mAbs evaluated in clinical trials. 18B7 mAb is a murine IgG1 that demonstrated acceptable safety in a phase I dose-escalation study in subjects with treated cryptococcal meningitis [136], but efficacy data for this therapy have not been generated. However, as reviewed by Larsen et al. [136], the administration of mAb against C. neoformans capsular polysaccharide to infected mice prolonged survival, reduced tissue burden, enhanced granuloma formation and enhanced antifungal activity of amphotericin B, fluconazole and flucytosine. These data support the continued investigation of this mAb.

Efungumab (Mycograb®) is a human genetically recombinant antibody that binds to the Candida heat-shock protein 90 (HSP90), preventing a conformational change needed for fungal viability [137]. Mycograb® showed protective activity against several Candida species and synergized with antifungal drugs when evaluated in vitro and in preclinical studies [138140]. In a clinical trial, the treatment with lipid-associated amphotericin B in combination with Mycograb® produced significant clinical improvement in outcome for patients with invasive candidiasis [141] when compared with the lipid-associated amphotericin B monotherapy. However, due to production difficulties, safety and quality issues, the drug was refused to grant marketing authorization.

Another immunoglobulin-based strategy was the production of anti-idiotypic monoclonal antibodies [142]. These mAbs that specifically reacting with killer toxins (KT) from Pichia anomala and Williopsis mrakii have broad antimicrobial spectrum and demonstrated in vitro similar activity to polymorphonuclear neutrophils against the hyphae and germinated conidia of A. fumigatus and in vivo protected immunocompromised mice with invasive aspergillosis from infection [143]. Similar results were observed against C. albicans in vitro and in vaginal and systemic murine models of candidiasis [144, 145].

Radioimmunotherapy uses the interactions between a fungal antigen and antibodies labeled with radionuclides to deliver cytocidal amounts of ionizing radiation to the specific target [146]. The advantages attributed to this immunotherapeutic method over standard antifungal therapy include: (a) it completely destroys the target cell by lethal radiation, delivers without the need of interaction with specific metabolism of the pathogen; (b) it is less subject to drug resistance mechanisms and does not suffer the drug-drug interactions that can be observed with some antifungals and others drugs; (c) it may permit single or a limited number of doses for the treatment of fungal diseases in contrast to weeks, months or years required to combat certain mycoses with antifungal drugs; (d) mAbs can be radiolabeled to bind antigens shared by many pathogenic fungi, such as heat-shock protein 60, β-(1,3)-glucan, ceramide and melanin [146148].

Protection against experimental Cryptococcus neoformans and Histoplasma capsulatum infections was described using the radioimmunotherapy, whose mechanisms include killing of microorganism cells by “direct hit” and “cross-fire” effects, promotion of apoptosis-like death, cooperation with macrophages and modulation of the inflammatory response [149, 150]. The effects of this therapy on bystander mammalian cells demonstrated minimal effects on host cells [151]. Reviews conducted to discuss the efficacy, toxicity, radiation resistance, radiobiological mechanisms and comparison with standard antifungal treatments [152] and the possibility of developing “panantibodies” for a universal treatment of the fungal diseases [148] suggest that this immunotherapeutic modality is a promising alternative for the treatment of invasive fungal infections.

Antibodies like anti-β-glucans demonstrated protection against A. fumigatus, C. albicans and Cryptococcus neoformans [153155]. Similarly, anti-melanin antibodies inhibit the growth and protection against C. neoformans and Fonsecaea pedrosoi and potential cross-resistance against various other fungi [156, 157].

Although most studies evaluate the antibodies that neutralize or kill the fungal pathogens [132], is growing the interest in the development of antibodies that can modulate the immune system and bring benefits to the host. For instance, through different immunomodulatory processes, 3B4 antibody protected mice from C. albicans-induced death in passive immunization [158], an agonist antibody CD40 prolonged the survival time of mice infected with Cryptococcus neoformans [159], anti-CD25 treatment decreased disease severity in the progressive and regressive forms of paracoccidioidomycosis [160], anti-PD-1 and anti-PD-L1 mAbs improved survival in fungal sepsis by C. albicans [161] and anti-CD3 antibody rapidly reversed the pathologic immune response caused by Pneumocystis carinii in a murine model of pneumonia [162].

Advertisement

6. Antifungal vaccines

The evaluation of antifungal vaccines has a great interest, but their development is challenging [10]. Antifungal vaccines are becoming a need in clinical settings, principally of immunocompromised and debilitated patients who are more prone to develop aggressive fungal infections. However, its use is limited by the weak immune response of these patients to respond vigorously to vaccination [163]. In this way, researchers made considerable progress in the last years, leading to more specific and well-characterized vaccines. Indeed, many antifungal vaccine candidates had been reported, and some have undergone preclinical evaluation and at least two are on the phase I clinical trials [164].

Studies on vaccination against fungal infections are conducted with whole-cell inactivated, live or attenuated fungi, cell wall subunits and the transfer of passive or adoptive immunity [165]. Usually, whole-cell inactivated vaccines are poorly immunogenic and have the disadvantage of having a complex chemical composition making it difficult to standardize [163]. In contrast, live virulence-attenuated vaccines are the best immunogens to achieve protection, but are unsafe in immunocompromised or otherwise debilitated patients, and even attenuated microorganisms can sometime cause disease in this subset [165]. In this way, subunit vaccines could be the best choice with regard to standardization and safety, but it lacks the natural adjuvant properties of whole-cell or live vaccines and usually needed an adjuvant to increase immunogenicity [10]. In animal models, the use of adjuvants is not a problem, since various adjuvants, such as Freund and aluminum hydroxide among others, have been very useful, but in humans, there is a scarcity of good adjuvants suitable for use in clinical practice [165]. Several adjuvants have been tested in recent years like the use of liposomes, virosomes, fungal immunogenic moieties and other bioengineered preparations and have proven useful [165, 166].

Protective immunity triggered by vaccination depends on both T-cell responses, particularly Th1 and/or Th17, and antibody responses which in turn are dependent on the kind of immunogens delivered to immune system [165]. A study conducted with a hyphal sonicate of A. fumigatus administered subcutaneously in corticosteroid immunosuppressed mice demonstrated that it was capable of conferring protection against invasive pulmonary aspergillosis [167]. Several studies have been conducted using the culture hypha filtrate, sonicated or vortexed hypha and demonstrated some degree of protection [168171]. PitiumVac®, a licensed immunotherapy to treat equine pythiosis in Brazil, is an example of the use of disrupted hyphae, and its use reaches a cure rate of 70–80% [172, 173]. Despite the good curative properties of PitiumVac®, it does not present protective activity [174].

Various investigations have reported that heat-killed yeasts (HKY) of Saccharomyces cerevisiae given subcutaneously in mice are protective against fungi from five genera: Aspergillus, Coccidioides, Cryptococcus, Candida and Rhizopus [175179]. Analysis of the underlying immune responses associated with HKY-induced protection of the host suggested that HKY vaccination induces significant and specific Th1 response and antibodies to glucan and mannan [180]. The components of HKY responsible for the cross-protective response against these infections are not known, but several homologous proteins and key cell wall glycan components shared among fungi have been described [177, 181, 182]. These results in combination with studies that demonstrated the safety of yeast-based vaccines in humans are suggestive that a pan-fungal yeast-based vaccine is possible [178, 183].

A recombinant live attenuated strain of Blastomyces dermatitidis null for the adhesion BAD1 (identified as a virulence factor) given subcutaneously as a vaccine protects mice from a lethal blastomycosis infection, and a Th1 response was linked with vaccine-induced resistance [184]. A study about safety, toxicity and immunogenicity of this vaccine in dogs proved to be save, well tolerated and the cytokine profile observed belonging to Th1 response (INF-γ, TNF-α and GM-CSF) [185]. Subsequent study, with this same vaccine, demonstrated that a Th1 response is dispensable and that Th17 cells are sufficient for vaccine-induced protection against a lethal pulmonary blastomycosis in mice [23]. Indeed, other two different live attenuated vaccines prepared with strains of Histoplasma capsulatum and Coccidiodes posodassi were tested and were found to protect mice from these endemic mycoses by a mechanism dependent upon Th17 cells [23, 186]. Another experimental live attenuated vaccine has been tested against hematogenously disseminated candidiasis, and it is based on a genetically engineered C. albicans tet-NRG1. Under certain conditions, this strain remains in the yeast phase and is nonpathogenic when administered to mice as a vaccine and resulted in substantial protection from virulent strain [187].

Advertisement

7. Fungal antigens

Components from fungal cell are able to modulate the Th response, particularly the molecules from their cell wall components, notably carbohydrates and glycoproteins, which are related to the induction of a Th1 and/or Th17 responses [12, 188]. These carbohydrates include β-glucans (β-1,3-linked polymers of glucose with β-1,6 branches), chitin (homopolymer of N-acetylglucosamine) and mannans (mannose chains of varying lengths and configurations added to fungal proteins through N- or O-linkages) [16]. In addition, some fungal proteins appear to activate monocytes and can be used as adjuvants in specific immunotherapy.

Fungal β-glucans activity has been researched for over 50 years with the focus principally on the glucans from yeasts (S. cerevisiae) and mushrooms (Lentinan edodes, Schizophyllun commune and Ganoderma lucidum) [189, 190]. Most of the fungal β-glucans markedly stimulate the immune system, and they are considered as biological response modifiers with pronounced immunomodulating activity against infectious disease and cancer [191]. Different immunological pathways have been related to the biological activities of β-glucans, as well as improvement in phagocytosis and proliferative activities of professional phagocytes (i.e., granulocytes, monocytes, macrophages and dendritic cells), T and NK cells stimulation, and activation of the alternative pathway of complement [192]. In mammals, β-glucans are recognized by dectin-1 and complement receptor 3 (CR3), and its preparations derived from fungi have a record of safety in both preclinical and human trials [193, 194].

Torosantucci et al. [154] were the first to link the use of a β-glucan and the induction of protective antibodies against different fungal infections. In their study was used the algal glucan laminarin conjugated with the diphtheria toxoid CRM197 for mice immunization that showed the ability of this glycoconjugate vaccine to confer protection against both lethal infections of C. albicans and A. fumigatus. This ability of a nonfungal β-glucan to induce specific anti β-glucan antibodies against two different pathogenic fungi highlights the possibility of the development of a single vaccine protecting against different fungal infections [195, 196]. This β-glucan CRM197 conjugated vaccine is in preclinical phase of development for aspergillosis, candidiasis and cryptococcosis [197]. Recent works using highly purified particulate β-glucan from S. cerevisiae alone or conjugated with bovine serum albumin (BSA) demonstrated the pluripotent activity of this vaccine in protection against experimental aspergillosis and coccidioidomycosis [198, 199]. Once β-glucans are highly conserved molecules, common to many fungi and that are able to induce protective antibodies, this implies that β-glucan would be an important vaccine component. Therefore, all these findings provide the basis for the future development of a pan-fungal conjugate vaccine [197].

Mannans, another carbohydrate from the fungal cell wall, have been implicated a long time ago with the host protective response against candidiasis [200]. Pioneering studies demonstrated that a vaccine containing a liposome-encapsulated mannan from C. albicans was protective in disseminated candidiasis in mice and that the specific antibodies produced were at least partly responsible for the protection with a β-1,2-linked mannotriose being the active epitope [201, 202]. Liposomal encapsulation was required because the extract alone was poorly immunogenic, and in an attempt to improve this formulation, new studies were made by conjugating mannan extract to protein (BSA) [203, 204]. This same C. albicans mannan conjugated to BSA presented cross-protective activity against systemic murine aspergillosis [205]. A study with S. cerevisiae mannan demonstrated the change of a T-cell-independent response when the polysaccharide was administered alone for a T-cell-dependent response when it was conjugated to human serum albumin (HSA). This study was conducted in mice and showed the increase in specific IgG isotype antibodies, mainly Th1 associated (IgG2a and IgG2b), making it a vaccine candidate for preventive immunomodulation treatment [206]. A synthetic β-mannan trisaccharide conjugated to different peptides found in C. albicans cell wall proteins was demonstrated to induce protective immunity in mice against candidiasis [55]. A tricomponent conjugate vaccine that associated the β-mannan trisaccharide, tetanus toxoid and laminarin was capable to promote multiple immune pathways leading to DC activation, induction of Th17 response and a potent immunization [207].

Glucuronoxylomannan (GXM), the major capsular polysaccharide of Cryptococcus neoformans, exerts many immunoregulatory effects, and in humans, the development of anticapsular antibodies is correlated with improved prognosis [208]. Conjugated vaccines of GXM-tetanus toxoid elicit protective antibodies in mice [209, 210], although deleterious antibodies can also be induced [211, 212]. This contradictory effect (protective v deleterious antibodies) can be avoided using GXM epitopes that elicit only protective antibodies, and it was observed coupling a derived GXM heptasaccharide to a protein carrier [212] and this vaccine is in phase I clinical trial [197]. The mimotope-based immunization can elicit an antibody response to a protective epitope on the native antigen [213]. The GXM peptide mimotope P13 conjugated to a protein carrier has demonstrated its effectiveness in prolonging survival of mice after a lethal challenge with C. neoformans, and the protection was associated with a reduction of serum levels of GXM and the production of antibodies to GXM [214216].

Once carbohydrates are known to produce T-cell-independent immune responses with a poor-quality antibody response, the conjugation with immunogenic protein carriers is a strategy to overcome this poor immunogenicity [217, 218]. Immunization with glycoconjugated vaccines elicit T cell help for B cells that produce IgG antibodies and can induce memory B-cell development and T-cell memory [219]. The main carrier proteins used in licensed conjugate vaccines are the enzymatically inactive and nontoxic variant of diphtheria toxin (CRM197), diphtheria toxoid (DT) and tetanus toxoid (TT) [220, 221].

On the other hand, protein antigens are highly immunogenic, elicit a strong T-cell response and are biochemically defined, which facilitate the large-scale production of recombinant proteins [222]. Indeed, two vaccines based on recombinant proteins of C. albicans are under phase I clinical trials [165]. The first vaccine is based on a recombinant N-terminus of the candida adhesion, Als3p (rAls3p-N) with alum as adjuvant, and elicits Th1 and Th17 cells [223]. The target of this vaccine included systemic and mucosal candidiasis, and the study in human subjects has been performed by NovaDigm Therapeutics [224]. Data from safety and immunogenicity have been posted on the web (www.novadigm.net). The second vaccine is based on the recombinant secretory aspartyl proteinase2, Sap2 [225] and appears to confer protection by Sap-neutralizing antibodies. This active vaccine, named PEV7, is targeted to prevent recurrent vulvovaginitis and is being developed by Pevion Biotech. Initial report about safety and immunogenicity profile of PEV7 in women is strongly encouraging (www.pevion.com).

Protein and glycoprotein from different pathogenic fungi have been studied, and particularly, heat-shock proteins (HSPs) represent an attractive candidate due to their association with both innate and adaptive immunity [226, 227]. Immunization with HSPs from Paracoccidioides brasiliensis has been shown to provide some degree of protection against experimental disease [228, 229]. Protective immune response has been also observed with native or recombinant (r) HSP60 from Histoplasma capsulatum, and rHSP60 reduced fungal burden and improved survival in experimental pulmonary histoplasmosis [230, 231]. Immunization with whole glycoprotein gp43 from P. brasiliensis demonstrated a dual response, inducing Th1 and Th2 cells, whereas the P10 (15-mer peptide derived from gp43) elicited Th1 response that protected mice from experimental paracoccidioidomycosis [232].

Summarizing all these studies with several pathogenic fungi has shown that antibodies against cell surface molecules could be implicated in the protective response to infection. The goal is to identify which molecules or epitopes are able to produce only protective antibodies and not those isotypes that inhibit host defenses or exert a negative effect on immunity. Despite a growing medical need and all efforts made by researchers, there is still no approved vaccine against any fungal disease.

Advertisement

8. Conclusion

Breakthroughs in our understanding of how homeostasis is established, maintained or disrupted during fungal exposure and/or colonization should help to guide the development of new therapeutics that target specific inflammatory or metabolic end points. For example, limiting inflammation—through PRR agonism or antagonism—to stimulate a protective immune response to fungi should pave the way for the rational design of novel immunomodulatory therapies.

References

  1. 1. Blackwell M. The fungi: 1, 2, 3 … 5.1 million species? Am J Bot. 2011;98:426–438.
  2. 2. Kohler JR, Casadevall A, and Perfect J. The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med. 2015;5:a019273.
  3. 3. Cui L, Morris A, and Ghedin E. The human mycobiome in health and disease. Genome Med. 2013;5:63.
  4. 4. Casadevall A and Pirofski LA. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun. 1999;67:3703–3713.
  5. 5. Pirofski LA and Casadevall A. What is infectiveness and how is it involved in infection and immunity? BMC Immunol. 2015;16:13.
  6. 6. Pirofski LA and Casadevall A. The damage-response framework of microbial pathogenesis and infectious diseases. Adv Exp Med Biol. 2008;635:135–146.
  7. 7. Seed PC. The human mycobiome. Cold Spring Harb Perspect Med. 2015;5:a019810.
  8. 8. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, and White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv113.
  9. 9. Perfect JR. “Is there an emerging need for new antifungals?”. Expert Opin Emerg Drugs. 2016;21:129–131.
  10. 10. Iannitti RG, Carvalho A, and Romani L. From memory to antifungal vaccine design. Trends Immunol. 2012;33:467–474.
  11. 11. Pflughoeft KJ and Versalovic J. Human microbiome in health and disease. Annu Rev Pathol. 2012;7:99–122.
  12. 12. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011;11:275–288.
  13. 13. Steele C and Wormley FL, Jr. Immunology of fungal infections: lessons learned from animal models. Curr Opin Microbiol. 2012;15:413–419.
  14. 14. Netea MG, Brown GD, Kullberg BJ, and Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol. 2008;6:67–78.
  15. 15. Thiemann S and Baum LG. Galectins and immune responses-just how do they do those things they do? Annu Rev Immunol. 2016;34:243–264.
  16. 16. Levitz SM. Innate recognition of fungal cell walls. PLoS Pathog. 2010;6:e1000758.
  17. 17. Wuthrich M, Deepe GS, Jr., and Klein B. Adaptive immunity to fungi. Annu Rev Immunol. 2012;30:115–148.
  18. 18. Borghi M, Renga G, Puccetti M, Oikonomou V, Palmieri M, Galosi C, Bartoli A, and Romani L. Antifungal Th Immunity: Growing up in Family. Front Immunol. 2014;5:506.
  19. 19. Perfect JR. The impact of the host on fungal infections. Am J Med. 2012;125:S39–51.
  20. 20. Romani L. Immune resistance and tolerance to fungi. G Ital Dermatol Venereol. 2013;148:551–561.
  21. 21. van de Veerdonk FL and Netea MG. T-cell subsets and antifungal host defenses. Curr Fungal Infect Rep. 2010;4:238–243.
  22. 22. Bar E, Whitney PG, Moor K, Reis e Sousa C, and LeibundGut-Landmann S. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity. 2014;40:117–127.
  23. 23. Wuthrich M, et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Invest. 2011;121:554–568.
  24. 24. Zelante T, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007;37:2695–2706.
  25. 25. Belkaid Y and Tarbell K. Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol. 2009;27:551–589.
  26. 26. Hickey MJ and Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. Nat Rev Immunol. 2009;9:364–375.
  27. 27. Shoham S and Levitz SM. The immune response to fungal infections. Br J Haematol. 2005;129:569–582.
  28. 28. Grigull L, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer. 2006;14:783–786.
  29. 29. Seidel MG, Peters C, Wacker A, Northoff H, Moog R, Boehme A, Silling G, Grimminger W, and Einsele H. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008;42:679–684.
  30. 30. Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007;44:15–23.
  31. 31. Ang AL and Linn YC. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era--experience from an adult haematology unit in Singapore. Transfus Med. 2011;21:13–24.
  32. 32. Strumia MM. The effect of leukocytic cream injections in the treatment of the neutropenias. Am J Med Sci. 1934;187:527–544.
  33. 33. Brecher G, Wilbur K, and Cronkite E. Transfusion of separated leukocytes into irradiated dogs with aplastic marrows. Exp Biol Med. 1953;84:54–56.
  34. 34. Freireich EJ, Levin RH, Whang J, Carbone PP, Bronson W, and Morse EE. The function and fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic recipients. Ann N Y Acad Sci. 1964;113:1081–1089.
  35. 35. Pedersen FK, Johansen KS, Rosenkvist J, Tygstrup I, and Valerius NH. Refractory Pneumocystis carinii infection in chronic granulomatous disease: successful treatment with granulocytes. Pediatrics. 1979;64:935–938.
  36. 36. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, and Neglia JP. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion (Paris). 1994;34:226–232.
  37. 37. Strauss RG. Granulocyte transfusion therapy. Hematol Oncol Clin North Am. 1994;8:1159–1166.
  38. 38. Strauss RG. Role of granulocyte/neutrophil transfusions for haematology/oncology patients in the modern era. Br J Haematol. 2012;158:299–306.
  39. 39. Chanock SJ and Gorlin JB. Granulocyte transfusions. Time for a second look. Infect Dis Clin North Am. 1996;10:327–343.
  40. 40. Bensinger WI, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993;81:1883–1888.
  41. 41. Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, and Dale DC. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302–3309.
  42. 42. Mousset S, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol. 2005;84:734–741.
  43. 43. Seidel MG, et al. Granulocyte transfusions in children and young adults: does the dose matter? J Pediatr Hematol Oncol. 2009;31:166–172.
  44. 44. Carter KB, Jr., Loehrl TA, and Poetker DM. Granulocyte transfusions in fulminant invasive fungal sinusitis. Am J Otolaryngol. 2012;33:663–666.
  45. 45. Kadri SS, Remy KE, Strich JR, Gea-Banacloche J, and Leitman SF. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion (Paris). 2015;55:2076–2085.
  46. 46. Safdar A, et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006;106:2664–2671.
  47. 47. Yoshihara S, Ikemoto J, and Fujimori Y. Update on granulocyte transfusions: accumulation of promising data, but still lack of decisive evidence. Curr Opin Hematol. 2016;23:55–60.
  48. 48. Ramirez-Ortiz ZG and Means TK. The role of dendritic cells in the innate recognition of pathogenic fungi (A. fumigatus, C. neoformans and C. albicans). Virulence. 2012;3:635–646.
  49. 49. Roy RM and Klein BS. Dendritic cells in antifungal immunity and vaccine design. Cell Host Microbe. 2012;11:436–446.
  50. 50. Perruccio K, Bozza S, Montagnoli C, Bellocchio S, Aversa F, Martelli M, Bistoni F, Velardi A, and Romani L. Prospects for dendritic cell vaccination against fungal infections in hematopoietic transplantation. Blood Cells Mol Dis. 2004;33:248–255.
  51. 51. Bozza S, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood. 2003;102:3807–3814.
  52. 52. Bozza S, Gaziano R, Lipford GB, Montagnoli C, Bacci A, Di Francesco P, Kurup VP, Wagner H, and Romani L. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 2002;4:1281–1290.
  53. 53. Shao C, Qu J, He L, Zhang Y, Wang J, Zhou H, Wang Y, and Liu X. Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis. Genes Immun. 2005;6:103–114.
  54. 54. Zhu F, Ramadan G, Davies B, Margolis DA, and Keever-Taylor CA. Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses. Clin Exp Immunol. 2008;151:284–296.
  55. 55. Xin H, Dziadek S, Bundle DR, and Cutler JE. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A. 2008;105:13526–13531.
  56. 56. Ueno K, et al. Dendritic cell-based immunization ameliorates pulmonary infection with highly virulent Cryptococcus gattii. Infect Immun. 2015;83:1577–1586.
  57. 57. Kalos M and June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39:49–60.
  58. 58. Papadopoulou A, Kaloyannidis P, Yannaki E, and Cruz CR. Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges. Crit Rev Oncol Hematol. 2016;98:62–72.
  59. 59. Perruccio K, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106:4397–4406.
  60. 60. Tramsen L, Schmidt S, Roeger F, Schubert R, Salzmann-Manrique E, Latge JP, Klingebiel T, and Lehrnbecher T. Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells. Infect Immun. 2014;82:2649–2656.
  61. 61. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, and Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol. 2000;165:381–388.
  62. 62. Stuehler C, et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood. 2011;117:5881–5891.
  63. 63. Stuehler C, Nowakowska J, Bernardini C, Topp MS, Battegay M, Passweg J, and Khanna N. Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J Infect Dis. 2015;211:1251–1261.
  64. 64. Tramsen L, Schmidt S, Boenig H, Latge JP, Lass-Florl C, Roeger F, Seifried E, Klingebiel T, and Lehrnbecher T. Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes. Cytotherapy. 2013;15:344–351.
  65. 65. Khanna N, Stuehler C, Conrad B, Lurati S, Krappmann S, Einsele H, Berges C, and Topp MS. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood. 2011;118:1121–1131.
  66. 66. Kumaresan PR, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A. 2014;111:10660–10665.
  67. 67. Zheng M, et al. Corrigendum. CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest. 2015;125:1364.
  68. 68. Cutler JE, Deepe GS, Jr., and Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol. 2007;5:13–28.
  69. 69. Sun Z, Zhu P, Li L, Wan Z, Zhao Z, and Li R. Adoptive immunity mediated by HLA-A*0201 restricted Asp f16 peptides-specific CD8+ T cells against Aspergillus fumigatus infection. Eur J Clin Microbiol Infect Dis. 2012;31:3089–3096.
  70. 70. Hoyt TR, Dobrinen E, Kochetkova I, and Meissner N. B cells modulate systemic responses to Pneumocystis murina lung infection and protect on-demand hematopoiesis via T cell-independent innate mechanisms when type I interferon signaling is absent. Infect Immun. 2015;83:743–758.
  71. 71. Bezman NA, et al. Molecular definition of the identity and activation of natural killer cells. Nat Immunol. 2012;13:1000–1009.
  72. 72. Cerwenka A and Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016;16:112–123.
  73. 73. Park SJ, Hughes MA, Burdick M, Strieter RM, and Mehrad B. Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis. J Immunol. 2009;182:4306–4312.
  74. 74. Bouzani M, Ok M, McCormick A, Ebel F, Kurzai O, Morton CO, Einsele H, and Loeffler J. Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. J Immunol. 2011;187:1369–1376.
  75. 75. Schmidt S, Tramsen L, Hanisch M, Latge JP, Huenecke S, Koehl U, and Lehrnbecher T. Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia. J Infect Dis. 2011;203:430–435.
  76. 76. Decker WK and Safdar A. Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease. Cytokine Growth Factor Rev. 2011;22:177–187.
  77. 77. Volpi I, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood. 2001;97:2514–2521.
  78. 78. Liles WC, Huang JE, van Burik JA, Bowden RA, and Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis. 1997;175:1012–1015.
  79. 79. Kullberg BJ, Netea MG, Vonk AG, and van der Meer JW. Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunol Med Microbiol. 1999;26:299–307.
  80. 80. Sionov E, Mendlovic S, and Segal E. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother. 2005;56:594–597.
  81. 81. Roden MM, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–653.
  82. 82. Smith TJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205.
  83. 83. Ringden O, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22:416–423.
  84. 84. Kuhara T, Uchida K, and Yamaguchi H. Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection. Antimicrob Agents Chemother. 2000;44:19–23.
  85. 85. Gonzalez CE, et al. Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. Cytokine. 2001;15:87–95.
  86. 86. Nemunaitis J, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood. 1993;82:1422–1427.
  87. 87. Vora S, Purimetla N, Brummer E, and Stevens DA. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother. 1998;42:907–910.
  88. 88. Brummer E, Maqbool A, and Stevens DA. In vivo GM-CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages. J Leukoc Biol. 2001;70:868–872.
  89. 89. Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, and Kleinerman ES. Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother. 2008;52:716–718.
  90. 90. Wildbaum G, Shahar E, Katz R, Karin N, Etzioni A, and Pollack S. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restoration of IL-17 secretion. J Allergy Clin Immunol. 2013;132:761–764.
  91. 91. Safdar A, Rodriguez G, Zuniga J, Al Akhrass F, Georgescu G, and Pande A. Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease. Acta Haematol. 2013;129:26–34.
  92. 92. Wan L, et al. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial. J Clin Oncol. 2015;33:3999–4006.
  93. 93. Netea MG, Kullberg BJ, and Van der Meer JW. Proinflammatory cytokines in the treatment of bacterial and fungal infections. Biodrugs. 2004;18:9–22.
  94. 94. Antachopoulos C and Roilides E. Cytokines and fungal infections. Br J Haematol. 2005;129:583–596.
  95. 95. Jarvis JN, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012;26:1105–1113.
  96. 96. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, Aberg J, Hasbun R, and Hsu HH. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis. 2004;189:2185–2191.
  97. 97. Gaviria JM, van Burik JA, Dale DC, Root RK, and Liles WC. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis. 1999;179:1038–1041.
  98. 98. Clemons KV, Lutz JE, and Stevens DA. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother. 2001;45:686–689.
  99. 99. Kullberg BJ, van’t Wout JW, Hoogstraten C, and van Furth R. Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis. 1993;168:436–443.
  100. 100. Mehrad B, Strieter RM, and Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol. 1999;162:1633–1640.
  101. 101. Shao C, Qu J, He L, Zhang Y, Wang J, Wang Y, Zhou H, and Liu X. Transient overexpression of gamma interferon promotes Aspergillus clearance in invasive pulmonary aspergillosis. Clin Exp Immunol. 2005;142:233–241.
  102. 102. Garner RE, Kuruganti U, Czarniecki CW, Chiu HH, and Domer JE. In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon. Infect Immun. 1989;57:1800–1808.
  103. 103. Perfect JR, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50:291–322.
  104. 104. Delsing CE, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis. 2014;14:166.
  105. 105. Al-Tawfiq JA and Al-Abdely HM. Vertebral osteomyelitis due to Aspergillus fumigatus in a patient with chronic granulomatous disease successfully treated with antifungal agents and interferon-gamma. Med Mycol. 2010;48:537–541.
  106. 106. Kelleher P, Goodsall A, Mulgirigama A, Kunst H, Henderson DC, Wilson R, Newman-Taylor A, and Levin M. Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J. 2006;27:1307–1310.
  107. 107. Saulsbury FT. Successful treatment of Aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis. 2001;32:E137–139.
  108. 108. Estrada C, Desai AG, Chirch LM, Suh H, Seidman R, Darras F, and Nord EP. Invasive aspergillosis in a renal transplant recipient successfully treated with interferon-gamma. Case Rep Transplant. 2012;2012:493758.
  109. 109. Abzug MJ and Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23:769–773.
  110. 110. Segal BH and Romani LR. Invasive aspergillosis in chronic granulomatous disease. Med Mycol. 2009;47:S282–290.
  111. 111. Romani L, Puccetti P, and Bistoni F. Interleukin-12 in infectious diseases. Clin Microbiol Rev. 1997;10:611–636.
  112. 112. Decken K, Kohler G, Palmer-Lehmann K, Wunderlin A, Mattner F, Magram J, Gately MK, and Alber G. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun. 1998;66:4994–5000.
  113. 113. Antachopoulos C and Walsh TJ. Immunotherapy of Cryptococcus infections. Clin Microbiol Infect. 2012;18:126–133.
  114. 114. Jiang C, Magee DM, and Cox RA. Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental coccidioidomycosis. Infect Immun. 1999;67:2996–3001.
  115. 115. Ruan S, McKinley L, Zheng M, Rudner X, D’Souza A, Kolls JK, and Shellito JE. Interleukin-12 and host defense against murine Pneumocystis pneumonia. Infect Immun. 2008;76:2130–2137.
  116. 116. Romani L, Bistoni F, Mencacci A, Cenci E, Spaccapelo R, and Puccetti P. IL12 in Candida albicans infections. Res Immunol. 1995;146:532–538.
  117. 117. Toren A, Or R, Ackerstein A, and Nagler A. Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT). Bone Marrow Transplant. 1997;20:67–69.
  118. 118. Vazquez N, Walsh TJ, Friedman D, Chanock SJ, and Lyman CA. Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans. Infect Immun. 1998;66:145–150.
  119. 119. Winn RM, Gil-Lamaignere C, Roilides E, Simitsopoulou M, Lyman CA, Maloukou A, and Walsh TJ. Selective effects of interleukin (IL)-15 on antifungal activity and IL-8 release by polymorphonuclear leukocytes in response to hyphae of Aspergillus species. J Infect Dis. 2003;188:585–590.
  120. 120. Winn RM, Gil-Lamaignere C, Roilides E, Simitsopoulou M, Lyman CA, Maloukou A, and Walsh TJ. Effects of interleukin-15 on antifungal responses of human polymorphonuclear leukocytes against Fusarium spp. and Scedosporium spp. Cytokine. 2005;31:1–8.
  121. 121. Musso T, et al. Interleukin-15 activates proinflammatory and antimicrobial functions in polymorphonuclear cells. Infect Immun. 1998;66:2640–2647.
  122. 122. Roilides E, Dimitriadou-Georgiadou A, Sein T, Kadiltsoglou I, and Walsh TJ. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun. 1998;66:5999–6003.
  123. 123. Kawakami K, Qureshi MH, Koguchi Y, Zhang T, Okamura H, Kurimoto M, and Saito A. Role of TNF-alpha in the induction of fungicidal activity of mouse peritoneal exudate cells against Cryptococcus neoformans by IL-12 and IL-18. Cell Immunol. 1999;193:9–16.
  124. 124. Mencacci A, Cenci E, Bacci A, Montagnoli C, Bistoni F, and Romani L. Cytokines in candidiasis and aspergillosis. Curr Pharm Biotechnol. 2000;1:235–251.
  125. 125. Gresnigt MS, Rosler B, Jacobs CW, Becker KL, Joosten LA, van der Meer JW, Netea MG, Dinarello CA, and van de Veerdonk FL. The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol. 2013;43:416–426.
  126. 126. Ketelut-Carneiro N, Silva GK, Rocha FA, Milanezi CM, Cavalcanti-Neto FF, Zamboni DS, and Silva JS. IL-18 triggered by the Nlrp3 inflammasome induces host innate resistance in a pulmonary model of fungal infection. J Immunol. 2015;194:4507–4517.
  127. 127. Unsinger J, Burnham CA, McDonough J, Morre M, Prakash PS, Caldwell CC, Dunne WM, Jr., and Hotchkiss RS. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis. 2012;206:606–616.
  128. 128. Kawakami K, Qureshi MH, Zhang T, Okamura H, Kurimoto M, and Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J Immunol. 1997;159:5528–5534.
  129. 129. Schroeder HW, Jr. and Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125:S41–52.
  130. 130. Strugnell RA and Wijburg OL. The role of secretory antibodies in infection immunity. Nat Rev Microbiol. 2010;8:656–667.
  131. 131. Parren PW, Poignard P, Ditzel HJ, Williamson RA, and Burton DR. Antibodies in human infectious disease. Immunol Res. 2000;21:265–278.
  132. 132. Casadevall A and Pirofski LA. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe. 2012;11:447–456.
  133. 133. Rivera J and Casadevall A. Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J Immunol. 2005;174:8017–8026.
  134. 134. Dromer F, Charreire J, Contrepois A, Carbon C, and Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun. 1987;55:749–752.
  135. 135. Gigliotti F and Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest. 1988;81:1666–1668.
  136. 136. Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, Cloud GA, James R, Filler S, and Dismukes WE. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother. 2005;49:952–958.
  137. 137. Karwa R and Wargo KA. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009;43:1818–1823.
  138. 138. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C, and Burnie J. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother. 2003;47:2208–2216.
  139. 139. Hodgetts S, Nooney L, Al-Akeel R, Curry A, Awad S, Matthews R, and Burnie J. Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemother. 2008;61:1132–1139.
  140. 140. Nooney L, Matthews RC, and Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis. 2005;51:19–29.
  141. 141. Pachl J, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;42:1404–1413.
  142. 142. Magliani W, Conti S, Gerloni M, Bertolotti D, and Polonelli L. Yeast killer systems. Clin Microbiol Rev. 1997;10:369–400.
  143. 143. Cenci E, et al. Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun. 2002;70:2375–2382.
  144. 144. Polonelli L, Magliani W, Conti S, Bracci L, Lozzi L, Neri P, Adriani D, De Bernardis F, and Cassone A. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun. 2003;71:6205–6212.
  145. 145. Polonelli L, et al. Yeast killer toxin-like candidacidal Ab6 antibodies elicited through the manipulation of the idiotypic cascade. PLoS One. 2014;9:e105727.
  146. 146. Nosanchuk JD and Dadachova E. Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens. Front Microbiol. 2011;2:283.
  147. 147. Bryan RA, Jiang Z, Howell RC, Morgenstern A, Bruchertseifer F, Casadevall A, and Dadachova E. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J Infect Dis. 2010;202:633–637.
  148. 148. Bryan RA, et al. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia. 2012;173:463–471.
  149. 149. Dadachova E and Casadevall A. Treatment of infection with radiolabeled antibodies. Q J Nucl Med Mol Imaging. 2006;50:193–204.
  150. 150. Dadachova E and Casadevall A. Radioimmunotherapy of infectious diseases. Semin Nucl Med. 2009;39:146–153.
  151. 151. Bryan RA, Jiang Z, Morgenstern A, Bruchertseifer F, Casadevall A, and Dadachova E. Radioimmunotherapy of Cryptococcus neoformans spares bystander mammalian cells. Future Microbiol. 2013;8:1081–1089.
  152. 152. Dadachova E and Casadevall A. Cryptococcus neoformans as a model for radioimmunotherapy of Infections. Interdiscip Perspect Infect Dis. 2011;2011:830286.
  153. 153. Torosantucci A, et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One. 2009;4:e5392.
  154. 154. Torosantucci A, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med. 2005;202:597–606.
  155. 155. Rachini A, et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun. 2007;75:5085–5094.
  156. 156. Rosas AL, Nosanchuk JD, and Casadevall A. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect Immun. 2001;69:3410–3412.
  157. 157. Alviano DS, Franzen AJ, Travassos LR, Holandino C, Rozental S, Ejzemberg R, Alviano CS, and Rodrigues ML. Melanin from Fonsecaea pedrosoi induces production of human antifungal antibodies and enhances the antimicrobial efficacy of phagocytes. Infect Immun. 2004;72:229–237.
  158. 158. Li W, et al. Host defence against C. albicans infections in IgH transgenic mice with V(H) derived from a natural anti-keratin antibody. Cell Microbiol. 2007;9:306–315.
  159. 159. Zhou Q, Gault RA, Kozel TR, and Murphy WJ. Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis. Infect Immun. 2006;74:2161–2168.
  160. 160. Felonato M, Pina A, de Araujo EF, Loures FV, Bazan SB, Feriotti C, and Calich VL. Anti-CD25 treatment depletes Treg cells and decreases disease severity in susceptible and resistant mice infected with Paracoccidioides brasiliensis. PLoS One. 2012;7:e51071.
  161. 161. Chang KC, et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care. 2013;17:R85.
  162. 162. Bhagwat SP, Wright TW, and Gigliotti F. Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J Immunol. 2010;184:497–502.
  163. 163. Pikman R and Ben-Ami R. Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections. Immunotherapy. 2012;4:1869–1882.
  164. 164. Lin L, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009;5:e1000703.
  165. 165. Cassone A and Casadevall A. Recent progress in vaccines against fungal diseases. Curr Opin Microbiol. 2012;15:427–433.
  166. 166. Hamad M. Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections. Scand J Immunol. 2008;67:533–543.
  167. 167. Ito JI and Lyons JM. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis. 2002;186:869–871.
  168. 168. Santurio JM, Leal AT, Leal AB, Festugatto R, Lubeck I, Sallis ES, Copetti MV, Alves SH, and Ferreiro L. Three types of immunotherapics against pythiosis insidiosi developed and evaluated. Vaccine. 2003;21:2535–2540.
  169. 169. Reichard U, Herrmann S, and Asif AR. Vaccination approaches against opportunistic fungal infections caused by Aspergillus fumigatus. Curr Protein Pept Sci. 2014;15:424–429.
  170. 170. Wormley FL, Jr., Cutright J, and Fidel PL, Jr. Multiple experimental designs to evaluate the role of T-cell-mediated immunity against experimental vaginal Candida albicans infection. Med Mycol. 2003;41:401–409.
  171. 171. Wanachiwanawin W, et al. Efficacy of immunotherapy using antigens of Pythium insidiosum in the treatment of vascular pythiosis in humans. Vaccine. 2004;22:3613–3621.
  172. 172. Watanabe MJ, de Moura Alonso J, Alves ALG, Yamada ALM, Bosco SdMG, Rodrigues CA, and Hussni CA. Equine pythiosis: report of 28 cases from São Paulo State, Brazil. Semina: Ciências Agrárias. 2015;36:909–916.
  173. 173. Santos C, Santurio J, Colodel E, Juliano R, Silva J, and MARQUES LC. Contribution to the study of cutaneous pythiosis in equidae. Ars Veterinaria. 2011;27:134–140.
  174. 174. Santos CE, Marques LC, Zanette RA, Jesus FP, and Santurio JM. Does immunotherapy protect equines from reinfection by the oomycete Pythium insidiosum? Clin Vaccine Immunol. 2011;18:1397–1399.
  175. 175. Liu M, Capilla J, Johansen ME, Alvarado D, Martinez M, Chen V, Clemons KV, and Stevens DA. Saccharomyces as a vaccine against systemic aspergillosis: ‘the friend of man’ a friend again? J Med Microbiol. 2011;60:1423–1432.
  176. 176. Capilla J, Clemons KV, Liu M, Levine HB, and Stevens DA. Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine. 2009;27:3662–3668.
  177. 177. Liu M, Clemons KV, Johansen ME, Martinez M, Chen V, and Stevens DA. Saccharomyces as a vaccine against systemic candidiasis. Immunol Invest. 2012;41:847–855.
  178. 178. Luo G, Gebremariam T, Clemons KV, Stevens DA, and Ibrahim AS. Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis. Vaccine. 2014;32:3573–3576.
  179. 179. Majumder T, Liu M, Chen V, Martinez M, Alvarado D, Clemons KV, and Stevens DA. Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii. Mycopathologia. 2014;178:189–195.
  180. 180. Liu M, Clemons KV, Bigos M, Medovarska I, Brummer E, and Stevens DA. Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine. 2011;29:1745–1753.
  181. 181. Champer J, et al. Protein targets for broad-spectrum mycosis vaccines: quantitative proteomic analysis of Aspergillus and Coccidioides and comparisons with other fungal pathogens. Ann N Y Acad Sci. 2012;1273:44–51.
  182. 182. Stevens DA, Clemons KV, and Liu M. Developing a vaccine against aspergillosis. Med Mycol. 2011;49(Suppl 1):S170–176.
  183. 183. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J, and Team VAERS. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. 2006;24:703–707.
  184. 184. Wüthrich M, Filutowicz HI, and Klein BS. Mutation of the WI-1 gene yields an attenuated Blastomyces dermatitidis strain that induces host resistance. J Clin Invest. 2000;106:1381–1389.
  185. 185. Wuthrich M, Krajaejun T, Shearn-Bochsler V, Bass C, Filutowicz HI, Legendre AM, and Klein BS. Safety, tolerability, and immunogenicity of a recombinant, genetically engineered, live-attenuated vaccine against canine blastomycosis. Clin Vaccine Immunol. 2011;18:783–789.
  186. 186. Wang H, LeBert V, Hung CY, Galles K, Saijo S, Lin X, Cole GT, Klein BS, and Wuthrich M. C-type lectin receptors differentially induce th17 cells and vaccine immunity to the endemic mycosis of North America. J Immunol. 2014;192:1107–1119.
  187. 187. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, and Lopez-Ribot JL. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun. 2008;76:97–102.
  188. 188. Goodridge HS, Wolf AJ, and Underhill DM. Beta-glucan recognition by the innate immune system. Immunol Rev. 2009;230:38–50.
  189. 189. Vetvicka V and Vetvickova J. Beta 1,3-glucan silver bullet or hot air? Open Glycoscience. 2010;3:1–6.
  190. 190. Giavasis I. Bioactive fungal polysaccharides as potential functional ingredients in food and nutraceuticals. Curr Opin Biotechnol. 2014;26:162–173.
  191. 191. Novak M and Vetvicka V. Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets. 2009;9:67–75.
  192. 192. Novak M and Vetvicka V. Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. J Immunotoxicol. 2008;5:47–57.
  193. 193. Weitberg AB. A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. J Exp Clin Cancer Res. 2008;27:40.
  194. 194. Williams DL, Sherwood ER, Browder IW, McNamee RB, Jones EL, and Di Luzio NR. Pre-clinical safety evaluation of soluble glucan. Int J Immunopharmacol. 1988;10:405–414.
  195. 195. Casadevall A and Pirofski L-a. Polysaccharide-containing conjugate vaccines for fungal disease. Trends Mol Med. 2006;12:6–9.
  196. 196. Bromuro C, et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine. 2010;28:2615–2623.
  197. 197. Astronomo RD and Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov. 2010;9:308–324.
  198. 198. Clemons KV, et al. Whole glucan particles as a vaccine against murine aspergillosis. J Med Microbiol. 2014;63:1750–1759.
  199. 199. Clemons KV, Antonysamy MA, Danielson ME, Michel KS, Martinez M, Chen V, and Stevens DA. Whole glucan particles as a vaccine against systemic coccidioidomycosis. J Med Microbiol. 2015;64:1237–1243.
  200. 200. Garner RE and Domer JE. Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis. Infect Immun. 1994;62:738–741.
  201. 201. Han Y and Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun. 1995;63:2714–2719.
  202. 202. Han Y, Kanbe T, Cherniak R, and Cutler JE. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun. 1997;65:4100–4107.
  203. 203. Han Y, Ulrich MA, and Cutler JE. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis. 1999;179:1477–1484.
  204. 204. Paulovičová E and Machová E. Candida albicans mannan–protein conjugate as vaccine candidate. Immunol Lett. 2003;85:251–255.
  205. 205. Liu M, Machova E, Nescakova Z, Medovarska I, Clemons KV, Martinez M, Chen V, Bystricky S, and Stevens DA. Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol. 2012;50:818–828.
  206. 206. Paulovičová E, Bystrický S, Masárová J, Machová E, and Mislovičová D. Immune response to Saccharomyces cerevisiae mannan conjugate in mice. Int Immunopharmacol. 2005;5:1693–1698.
  207. 207. Lipinski T, Fitieh A, St Pierre J, Ostergaard HL, Bundle DR, and Touret N. Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating beta-glucan. J Immunol. 2013;190:4116–4128.
  208. 208. Vecchiarelli A. Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol. 2000;38:407–417.
  209. 209. Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, and Scharff MD. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis. 1992;165:1086–1093.
  210. 210. Devi SJ. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine. 1996;14:841–844.
  211. 211. Mukherjee J, Nussbaum G, Scharff MD, and Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med. 1995;181:405–409.
  212. 212. Oscarson S, Alpe M, Svahnberg P, Nakouzi A, and Casadevall A. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures. Vaccine. 2005;23:3961–3972.
  213. 213. Datta K and Pirofski LA. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res. 2006;6:525–536.
  214. 214. Maitta RW, Datta K, Lees A, Belouski SS, and Pirofski LA. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun. 2004;72:196–208.
  215. 215. Fleuridor R, Lees A, and Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol. 2001;166:1087–1096.
  216. 216. Datta K, Lees A, and Pirofski LA. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin Vaccine Immunol. 2008;15:1176–1187.
  217. 217. Ada G and Isaacs D. Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect. 2003;9:79–85.
  218. 218. Avci FY, Li X, Tsuji M, and Kasper DL. Carbohydrates and T cells: a sweet twosome. Semin Immunol. 2013;25:146–151.
  219. 219. Anish C, Schumann B, Pereira CL, and Seeberger PH. Chemical biology approaches to designing defined carbohydrate vaccines. Chem Biol. 2014;21:38–50.
  220. 220. Shinefield HR. Overview of the development and current use of CRM 197 conjugate vaccines for pediatric use. Vaccine. 2010;28:4335–4339.
  221. 221. Tontini M, et al. Comparison of CRM 197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines. Vaccine. 2013;31:4827–4833.
  222. 222. Hole CR and Wormley FL, Jr. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol. 2012;3:291.
  223. 223. Spellberg B, Ibrahim AS, Lin L, Avanesian V, Fu Y, Lipke P, Otoo H, Ho T, and Edwards Jr JE. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis. 2008;197:967–971.
  224. 224. Hennessey Jr J, Schmidt C, Ibrahim A, Filler S, White C, Yeaman M, Fu Y, and Edwards J. A Phase 1 clinical evaluation of NDV3, a vaccine to prevent disease caused by Candidaspp. and Staphylococcus aureus. In 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. Washington, DC: American Society for Microbiology. 2011; of Conference; 2011 p.
  225. 225. Sandini S, La Valle R, Deaglio S, Malavasi F, Cassone A, and De Bernardis F. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol. 2011;62:215–224.
  226. 226. Segal BH, Wang XY, Dennis CG, Youn R, Repasky EA, Manjili MH, and Subjeck JR. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today. 2006;11:534–540.
  227. 227. Assis-Marques MA, Oliveira AF, Ruas LP, dos Reis TF, Roque-Barreira MC, and Coelho PS. Saccharomyces cerevisiae expressing Gp43 protects mice against Paracoccidioides brasiliensis infection. PLoS One. 2015;10:e0120201.
  228. 228. Ribeiro AM, Bocca AL, Amaral AC, Souza ACC, Faccioli LH, Coelho-Castelo AA, Figueiredo F, Silva CL, and Felipe MSS. HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis. Vaccine. 2010;28:1528–1534.
  229. 229. Ribeiro AM, Bocca AL, Amaral AC, Faccioli LH, Galetti FC, Zarate-Blades CR, Figueiredo F, Silva CL, and Felipe MS. DNAhsp65 vaccination induces protection in mice against Paracoccidioides brasiliensis infection. Vaccine. 2009;27:606–613.
  230. 230. Gomez FJ, Allendoerfer R, and Deepe GS, Jr. Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect Immun. 1995;63:2587–2595.
  231. 231. Deepe Jr GS and Gibbons RS. Cellular and molecular regulation of vaccination with heat shock protein 60 from Histoplasma capsulatum. Infect Immun. 2002;70:3759–3767.
  232. 232. Taborda CP, Juliano MA, Puccia R, Franco M, and Travassos LR. Mapping of the T-cell epitope in the major 43-kilodalton glycoprotein of Paracoccidioides brasiliensis which induces a Th-1 response protective against fungal infection in BALB/c mice. Infect Immun. 1998;66:786–793.

Written By

Érico S. Loreto, Juliana S. M. Tondolo, Sydney H. Alves and Janio M. Santurio

Submitted: June 1st, 2016 Reviewed: October 5th, 2016 Published: April 26th, 2017